Table 4 Drug exposure in each group, 14–3-3η
From: Prevalence and significance of serum 14–3-3η in juvenile idiopathic arthritis
JIA Type | NSAIDs | DMARDs | Biologics | |||
|---|---|---|---|---|---|---|
14–3-3η+ | 14–3-3η- | 14–3-3η+ | 14–3-3η- | 14–3-3η+ | 14–3-3η- | |
PJIA RF+ | 16/19 (84%) | 19/20 (95%) | 17/19 (89%) | 19/20 (95%) | 16/19 (84%) | 17/20 (85%) |
PJIA RF- | 1/3 (33%) | 30/36 (83%) | 2/3 (67%) | 33/36 (92%) | 3/3 (100%) | 31/36 (86%) |
ERA | 0/2 (0%) | 11/16 (69%) | 0 /2 (0%) | 11/16 (69%) | 1/2 (50%) | 14/16 (88%) |
PsA | 2/2 (100%) | 10/17 (59%) | 1/2 (50%) | 13/17 (76%) | 1/2 (50%) | 14/17 (82%) |
OJIA | 6/8 (75%) | 21/28 (75%) | 8 /8 (100%) | 21/28 (75%) | 3/8 (38%) | 12/28 (43%) |